Archive for December, 2013

Dermoscopy after topical treatment of BCC

I thought this is a very interesting study.

regards

Ian

 

Br J Dermatol. 2013 Nov 27. doi: 10.1111/bjd.12749. [Epub ahead of print]

Applicability of dermoscopy for evaluation of patients’ response to non-ablative therapies for the treatment of superficial basal cell carcinoma.

Source

State Clinic of Dermatology, Hospital of Skin and Venereal Diseases, Thessaloniki, Greece.

Abstract

BACKGROUND:

Applicability of dermoscopy in evaluation of outcome and monitoring of superficial basal cell carcinoma (sBCC) after non-ablative therapies has not been sufficiently assessed.

OBJECTIVE:

Certain dermoscopic criteria, namely pigmented structures, ulceration and arborizing vessels have been suggested to predict presence of residual disease (residual disease-associated dermoscopic criteria-RDADC). We aimed to assess this hypothesis.

METHODS:

Lesions exhibiting RDADC 3 months after treatment were biopsied and in case of histopathologic confirmation were excised. Lesions characterized by white/red structureless areas, superficial fine telangiectasias, or lacking any dermoscopic criterion, were monitored for 12 months.

RESULTS:

At the 3-month evaluation, one or more of the RDADC were detected in 25/98 (25.5%) sBCCs, in which histology confirmed tumor persistence. In 45(61.6%) of the 73 remaining lesions, dermoscopy showed red/white structureless areas and/or superficial fine telangiectasias. Twenty-eight lacked any dermoscopic criterion of sBCC. The two latter groups entered follow-up. In total, disease recurred in 13 (17.8%) of the 73 lesions.

CONCLUSIONS:

RDADC accurately predict residual disease. Absence of dermoscopic criteria of sBCC safely predicts complete histopathologic clearance. Detection of red/white structureless areas and/or superficial fine telangiectasias warrants close monitoring to recognize early recurrence.

Leave a comment